Focused On-demand Library for Receptor-type tyrosine-protein phosphatase U

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Pancreatic carcinoma phosphatase 2; Protein-tyrosine phosphatase J; Protein-tyrosine phosphatase pi; Protein-tyrosine phosphatase receptor omicron; Receptor-type protein-tyrosine phosphatase psi

Alternative UPACC:

Q92729; A6H8L1; O00197; P78399; Q59HA4; Q5SYU4; Q5SYU5; Q92735; Q92850


Receptor-type tyrosine-protein phosphatase U, known by alternative names such as Pancreatic carcinoma phosphatase 2 and Protein-tyrosine phosphatase receptor omicron, plays a pivotal role in cellular processes. It dephosphorylates CTNNB1, influencing cell adhesion, signaling, proliferation, and migration. This protein is also crucial in maintaining epithelial integrity and may contribute to megakaryocytopoiesis.

Therapeutic significance:

Understanding the role of Receptor-type tyrosine-protein phosphatase U could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.